Compare NPK & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPK | ORIC |
|---|---|---|
| Founded | 1905 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 945.9M | 861.3M |
| IPO Year | 1994 | 2020 |
| Metric | NPK | ORIC |
|---|---|---|
| Price | $125.90 | $8.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $19.73 |
| AVG Volume (30 Days) | 111.2K | ★ 1.8M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.71% | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | ★ 0.99 | N/A |
| Revenue | ★ $503,524,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $129.38 | ★ N/A |
| Revenue Growth | ★ 29.70 | N/A |
| 52 Week Low | $91.28 | $7.23 |
| 52 Week High | $149.86 | $14.93 |
| Indicator | NPK | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 40.36 | 56.51 |
| Support Level | $123.35 | $7.60 |
| Resistance Level | $147.26 | $9.13 |
| Average True Range (ATR) | 4.40 | 0.53 |
| MACD | 0.04 | 0.18 |
| Stochastic Oscillator | 18.10 | 91.22 |
National Presto Industries Inc has an electric product portfolio consisting of household appliances, ammunition, and diapers. The company operates in three segments, namely Defense, Housewares/Small Appliance, and Safety. The defense segment, which is engaged in manufacturing 40mm ammunition, precision mechanical and electro-mechanical assemblies, and medium caliber cartridge cases, performs Load, Assemble, and Pack (LAP) operations on ordnance-related products for the U.S. Government and prime contractor. While the Housewares/Small Appliance segment designs, markets, and distributes housewares and small electrical appliances, the safety segment provides safety technology empowering organizations and individuals to protect what is more important.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.